Compare Amplitude Inc (AMPL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Summit Therapeutics Inc — how do they compare? Amplitude Inc trades at $12.38 (market cap $1.59B), while Summit Therapeutics Inc trades at $15.08 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 7.6× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | SMMT | |
|---|---|---|
Market Cap | $1.59B | $12.06B |
Sector | Technology | Health |
52-Week High | $12.69 | $26.98 |
52-Week Low | $5.61 | $12.55 |
Enterprise Value | $1.45B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $12.37, up 1.48% today, with a bullish technical signal from moving averages. Revenue grew to $343.21M in 2025, but net losses persist at -$88.54M. Analyst consensus is bullish with a $12.08 price target, supported by enterprise and AI-driven growth initiatives highlighted in recent earnings calls. The stock shows strong institutional buy ratings despite negative profitability metrics.
Outlook remains cautiously optimistic due to revenue growth and AI expansion, but risks include sustained losses, cash flow deficits, and ongoing legal investigations. The stock's valuation at P/S 4.49 may appeal if profitability improves, yet high P/B 11.64 signals premium pricing relative to book value.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
